AngioDynamics signals FY2026 adjusted EBITDA of $10M-$12M while raising net sales guidance to $313.5M-$315.5M (NASDAQ:ANGO)April 2, 2026
Share Facebook Twitter LinkedIn Pinterest Email Rapid Dose Therapeutics announces proposed equity private placement financing
AngioDynamics signals FY2026 adjusted EBITDA of $10M-$12M while raising net sales guidance to $313.5M-$315.5M (NASDAQ:ANGO)April 2, 2026